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Abstract
Background: Stevens Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but fatal adverse skin
reactions that affect all age groups. In order to better understand literature on this topic, we conducted a bibliometric
study using Scopus database to shed light on number and growth of publications, most active countries, institutions,
journals and authors involved in publishing articles in this field, citation analysis, top cited articles, international
collaboration, role of medications and genetic association. Bibliometric analysis will enrich the literature on these rare
conditions and will provide baseline data for future comparison.
Results: Three thousand eight hundred fifty-six journal articles were retrieved. The h-index of retrieved
documents was 95. Growth rates of publications were highest from 1966 to 1975 and from 2006 to 2015. The
United States of America (n = 640; 16.57%) was the leading country in number of publications. However, French
and Japanese researchers and institutions were most active in publishing articles on SJS and TEN. International
collaboration among active countries was relatively low and ranges from 32.5% for Swiss researchers and 1.47%
for Spanish researchers. The most frequently mentioned medication in retrieved articles was carbamazepine
(n = 146) followed by phenytoin (n = 114) and allopurinol (n = 112). Mycoplasma infection was mentioned in
111 articles. Most documents on SJS and TEN were published in dermatology journals, specifically Archives of
Dermatology. However, in the last decade, top cited articles appeared in dermatology and pharmacogenetic
journals. Carbamazepine was frequently encountered with Han Chinese and HLA-B 1502 terms while allopurinol
was frequently encountered with HLA-B 5801 and Japanese terms.
Conclusion: Bibliometric analysis reveals that research publications on SJS and TEN have been increasing since
the l940s, with relatively low international collaboration. Documents are being published, not only in
dermatology journals, but also in genetic, public health and general medicine journals. Research on SJS and
TEN can be helpful to clinicians and researchers not only to document complications and fatal outcomes, but
also to identify potential causative agents and potential ethnic variations to note gaps in research.
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Background
Stevens-Johnson syndrome (SJS) and toxic epidermal
necrolysis (TEN) are uncommon, but serious and some-
times fatal adverse skin and mucous reactions [1]. Stevens
and Johnson were the first to describe SJS in 1922 while
Lyell was the first to describe TEN in 1956 [2, 3]. Up until
early 1990s, erythema multiforme major (EMM) and SJS
were considered similar clinical conditions. However, in
1993 EMM and SJS were identified as two distinct dis-
orders [4]. TEN and SJS are now considered part of a
continuum with SJS representing the less severe form
of the reaction, and TEN representing the more severe
end. The TEN involves larger total body surface area
than SJS. The “SJS/TEN” is considered an intermediate
form [5–7]. Incidence rates of TEN and SJS varies
across the studies but it is generally less than two cases
per million each year [7]. The reported mortality in pa-
tients with SJS varies from 3 to 10% while those with
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TEN have higher mortality rate and ranges from 20 to
40% [8]. The medical outcome of SJS and TEN varies
depending on the medical condition of the patient
when initiating therapy of the condition [9].
Both SJS and TEN are most often triggered by certain
medications, most commonly anticonvulsants, non-steroidal
anti-inflammatory drugs, and antibiotics [10, 11]. Un-
fortunately, a recent study showed that there is an
under reporting of drug – induced SJS and TEN [12].
Common over-the-counter drugs such as paracetamol
and ibuprofen have been reported in some cases of SJS
and TEN [13]. According to Stevens Johnson Syndrome
foundation (SJSF), any medication, including cocaine
and Ginseng containing herbal products, can cause SJS
and TEN [14]. Other causes of SJS and TEN include
certain infections [15]. For unclear reasons, it was found
that patients with human immune deficiency virus (HIV)
have higher risk of developing SJS and TEN compared to
un-infected people [7, 16–21]. Other infections such as
Mycoplasma pneumoniae infections and herpes simplex
viral infections were linked to SJS and TEN even without
previous exposure to medications [22–27]. SJS and TEN
are associated with certain HLA types [28–32]. The gen-
etic basis of SJS and TEN might be responsible for varia-
tions in reporting of drug-induced SJS and TEN in
different parts of the world [33]. Better understanding of
these variation can help in developing preventive and
therapeutic policies for SJS and TEN [34].
Being considered rare conditions, studies on SJS and
TEN are required. Such studies are beneficial for pharma-
cologists, clinical toxicologists, and clinicians in various
medical specialties such as dermatologists, pediatricians,
and critical care specialists. One method to enrich litera-
ture about a certain topic is to provide detailed analysis of
published literature on that particular topic. Such analysis
of literature is called bibliometric analysis. Therefore, this
study was carried out to give a bibliometric overview of
literature on TEN and SJS. Bibliometric analysis is not
intended to be a review article of scientific information on
TEN and SJS, rather an analysis of published literature in
terms of annual growth, productivity of various countries,
institutions and authors, international collaboration,
highly cited articles, and to lesser extent discussion of
the content of highly cited articles. Bibliometric analysis
on various medical subjects, including new subjects such
as telemedicine have been carried out and published
[35–44]. Such studies added new information to the
scientific literature of these conditions and added mo-
mentum to research aspects of these conditions. Rare
diseases and conditions should be given priority in
bibliometric studies to establish baseline data for future
comparison. Therefore, we believe that such a study
will be a positive addition to the field of rare diseases in
general and to SJS and TEN in particular.
Methods
In bibliometric studies, literature on a certain topic need
to be retrieved and analyzed as an initial step. To accom-
plish this, the largest database need to be used. Unfortu-
nately, no single database is perfect. However, Scopus
database is believed to be the largest and most accurate
when compared with other databases [45, 46]. Therefore,
for this study, Scopus was used and accessed through
Hinari website.
The keywords entered in Scopus search engine were
straight forward and consisted of “Toxic epidermal necro-
sis”, “Stevens-Johnson syndrome”, and “Lyell”s syndrome”.
These keywords were used in title search separated by
“OR” function. The time span of the study was determined
from 1940 to 2015. The search query was limited to
published journal articles with errata (corrections) doc-
uments being excluded. The search query looked like
this in Scopus: (TITLE(“Toxic epidermal necrolysis”) OR
TITLE(“Lyell”s syndrome”) OR TITLE(“Stevens-Johnson
syndrome”) AND (EXCLUDE(PUBYEAR,2016)) AND
(LIMIT-TO(SRCTYPE,“j”)) AND (EXCLUDE(DOCTYPE,“er”)).
One might question the validity of using title search in-
stead of title-abstract-keyword approach. The use of title-
abstract-keyword research will retrieve so many false posi-
tive results that will compromise the validity of retrieved
data. However, the use of title search will minimize both
false positive and false negative results. The validity of re-
trieved articles was based on manual check of the content
of 10% of retrieved documents across all years and found
to be free of false positive articles.
Retrieved articles can be analyzed from different as-
pects. Growth of publications was presented in decade
interval. Growth rate was determine by calculating the
difference in number of publications between two con-
secutive decades and dividing by the number of publica-
tions in the earlier decade. Scopus has the ability to rank
countries, institutions and authors based on the number
of articles they participated in. Articles with authors
having different country affiliation are called multiple
country publication (MCP) and considered to represent
international collaboration of that country. On the other
hand, articles in which all authors have the same country
affiliation are called single country publication (SCP)
and are considered to represent intra-country (within)
collaboration.
Scopus provides researchers with the opportunity to do
citation analysis. Retrieved documents can be sorted based
on number of citations they received. Top cited articles are
those that received the highest number of citations while
articles with a minimum number of 100 citations are con-
sidered to be highly cited articles. Scopus provides total ci-
tations for retrieved articles and Hirsch index (h-index).
Visualization and mapping of specific results could be
achieved through using a mapping program such as
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VOSviewer. In this study, data for countries, institutions,
authors, and journals were presented in tables on the
basis of a minimum contribution of 20 articles.
This study did not require approval of ethic committee
and therefore, approval of study by medical ethics com-
mittee was not sought. Data presentation did not involve
statistical analysis and Microsoft Excel program was used
to accomplish most of the data presented in this study.
Results
General information
Three thousand eight hundred fifty-six journal articles
were retrieved. The majority of retrieved articles were
research articles (n = 2948; 76.45%) followed by letters
(n = 529; 13.72%) and reviews (n = 211; 5.47%) (Table 1).
The majority of retrieved articled were written in English
(n = 2,575; 66.78%). Other encountered languages are
shown in Table 2. An article published in 1946 was the
oldest record of SJS and TEN in Scopus database [47].
The growth of publications on SJS and TEN is presented
in decade intervals in Fig. 1. The highest growth rates
were seen during the periods from 1956 to 1965 and
from 2006 to 2015. The annual growth of publication of
various types of journal articles is shown in Fig. 2.
Frequently encountered terms
Network visualization of most frequently encountered
terms is shown in Fig. 3. The map included four clusters:
the first cluster (red) included terms that describes the SJS
and TEN skin eruption and associated factors; the second
cluster (green) included terms pertaining to treatment and
potential outcome; the third cluster (blue) included terms
pertaining to medications and genetic association with
HLA types; and the fourth cluster (yellowish green) in-
cluded terms pertaining to ophthalmic complications of
SJS and TEN.
Citation analysis
Retrieved documents received a total of 4908 citations.
The mean ± standard deviation of number of citations per article was 12.73 ± 41.57 while the median (Q1 – Q3) was
2 (0 – 10). The h-index of retrieved documents was 95.
The cumulative number of citations showed a linear in-
crease with time indicative of continuous interest, read-
ability, and citations of SJS and TEN publications (Fig. 4).
The review article entitled “Medication use and the risk of
Stevens-Johnson syndrome or toxic epidermal necrolysis”
[48] published in New England Journal of Medicine
(NEJM) in 1995 received the highest number of citations
(938). A total of 87 articles (2.25%) were highly cited.
Top cited articles
Table 3 represents top cited articles across different time
periods. Top cited articles during the period from 1946
to 1985 were mainly published in dermatology journals
Table 1 Types of retrieved documents







Conference Paper 51 1.32
Short Survey 25 0.65
Editorial 15 0.39
Article in Press 7 0.18

































SJS Stevens – Johnson Syndrome
TEN Toxic Epidermal Necrolysis
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and the main theme of the top cited articles was descrip-
tion of SJS and TEN cases with emphasis on medication
– induced skin reactions. During the period from 1986
to 2005, the top cited articles were published in derma-
tology journals and prestigious general science journals
such as Nature and Science. The main theme of top
cited articles during that period was classification of the
condition, illness severity score, and molecular patho-
genesis of the SJS and TEN skin reaction. During the
time period from 2006 to 2015, top cited articles were
published in pharmacogenetic journals as well as derma-
tology journals. The emphasis of top cited articles during
that period was on the association between SJS. TEN,
medications, and HLA typing.
Fig. 1 Growth of publications on SJS and TEN presented in decade intervals
Fig. 2 Annual growth of publications of various types of retrieved journal articles
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Active countries
Researchers from 96 different countries contributed to
the advancement of knowledge on SJS and TEN. Table 4
shows a list of active countries which had published a
minimum of 20 publications on SJS and TEN. The total
number of publications produced by these active coun-
tries was 2640 (68.46%). The United States of America
(USA) (n = 640; 16.57%) ranked first in number of publi-
cations followed by Japan (n = 237; 6.14%), France (n =
234, 6.06%) and the United Kingdom (UK) (n = 199;
5.15%). When research productivity was stratified by
world region, the European union had the greatest share
followed by north America and Asia (Fig. 5a). Geo-
graphic distribution of research productivity is presented
in Fig. 5b.
Network visualization of citations received by articles
produced by active countries is shown in Fig. 6. Publi-
cations form the USA received the highest number of
citation followed by those from France, Germany, Italy
and the UK. The volume of citations is correlated with
size of the circle representing each country in network
visualization map.
International collaboration (MCP) was also assessed
for the active countries. Approximately one third of
Fig. 3 Network visualization of most frequently encountered terms
Fig. 4 Growth of publications versus number of cumulative citations
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articles (32.5%) produced by Switzerland had international
authors. In contrast, only 1.47% of articles produced by
Spain had lowest international authors. International col-
laboration among active countries is presented by network
visualization map (Fig. 7). The thickness of the link be-
tween any two countries represents the strength of collab-
oration while the size of the circle assigned for that
country represents the extent of international collabor-
ation. The network visualization map showed that the
strongest collaboration was between Germany and France.
The USA had the largest circle size indicative of the high-
est extent of international collaboration. The percentage
of MCP for the USA was not the highest. However, be-
cause of the very large number of published articles by the
USA, the extent of international collaboration by the USA
was the highest. When network visualization map was
presented as a density visualization map, countries such as
Germany, France, UK, Netherlands, Belgium, Israel, and
Italy were found in a close cluster while the USA, China,
Taiwan, Singapore, Thailand, and Australia were found in
a second close cluster suggestive of close collaboration.
Active institutions
Active institutions in publishing articles on SJS and TEN
were presented in Fig. 8. The most active institution
was Universite Paris 12 Val de Marne in France (n = 66;
1.71%) followed by Hospital Henri Mondor in France
(n = 58; 1.5%) and Kyoto Prefectural University of Medicine
in Japan (n = 40; 1.03%). The first two active institutions
were in France. When institutions with a minimum prod-
uctivity of ten articles were analyzed for country/territory
affiliation, the USA ranked first with eight institutions
followed by Italy with six institutions, France with five
institutions, Japan with five institutions, and Taiwan
with four institutions.
Active authors
Active authors in publishing about SJS and TEN are
shown in Table 5. Professor Roujeau, J.-C. from France
had the highest contribution with 113 articles. Further-
more, Professor Roujeau, J.-C. had the highest h-index.
Five active authors were French and three were Japanese.
The other active authors were from Germany and Belgium.
Co-citation analysis of active authors shows that Roujeau,
J.-C was the most commonly co-cited author followed by
Revuz, J. and Mockenhaupt, M (Fig. 9). Active authors were
mainly from France, japan, and Belgium
Active journals
Table 6 shows a list of 24 active journals involved in pub-
lishing articles on SJS and TEN. Each journal had pub-
lished at least 20 articles on SJS and TEN. As expected,
the majority of these journals were in the field of derma-
tology. Three journals were in the field of burns, two were
in the field of ophthalmology and two were in the field of
general medicine. Journal of Archives of Dermatology
ranked first in number of publications followed by British
Journal of Dermatology and Lancet. Citation analysis
showed that articles on SJS and TEN published in Ar-
chives of Dermatology received the highest number of cita-
tions while those published in Journal of The American
Table 3 Top 10 cited articles on SJS and TEN in three different time periods
Rank Top 10 cited articles for the time period
1946 – 1985
N = 1246
Top 10 cited articles for the time period
1986 - 2005
N = 1288
Top 10 cited articles for the time period
2006 – 2015
N = 1322
Reference Number of citation Reference Number of citation Reference Number of citation
1 392 [72] 938 [73] 404
2 [74] 159 [75] 829 [76] 321
3 [77] 153 [78] 825 [79] 299
4 [80] 101 [81] 771 [82] 278
5 [83] 94 [84] 438 [49] 244
6 [85] 89 [86] 393 [87] 230
7 [88] 86 [89] 325 [90] 206
8 [91] 75 [92] 322 [93] 205
9 [94] 72 [95] 316 [96] 178
10 [97] 66 [98] 288 [99] 173
Main journals 7 Dermatology 6 Dermatology 4 Dermatology and 4 Genetic
Main focus Descriptive studies, ocular
consequences, drug etiology
Illness severity Score,
classification of TEN, and molecular
aspects of therapy
Ethnic variations, role of genetics,
and anti-epileptics induced TEN
SJS Stevens – Johnson Syndrome
TEN Toxic Epidermal Necrolysis
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Academy of Dermatology and British Journal of Dermatol-
ogy ranked second and third respectively (Fig. 10).
Drug induced SJS and TEN, co-morbid conditions, and
complications
The most commonly encountered medication in retrieved
documents was carbamazepine which was mentioned in
146 documents followed by phenytoin which was men-
tioned in 114 and allopurinol which was mentioned in
112. Lamotrigene was mentioned in 93 documents while
the antiviral nevirapine was mentioned in 53. Other
mentioned medications include: valproic acid (n = 50),
phenobarbital (n = 45), and sulfamethoxazole (n = 44).
The over-the counter analgesic, paracetamol/acetaminophen
was mentioned in 37 documents. Other causative
agents include infections which include mycoplasma that
had been mentioned in 111 documents. Other infectious
agents include cytomegalovirus which was mentioned in
seven documents. Vaccinations as a causative agent had
been mentioned in 26 documents.
Human immune deficiency virus was co-mentioned
in a total of 116 documents on SJS and TEN while
cancer was co-mentioned in 91, tuberculosis in 29,
hypertension in 19, and diabetes mellitus in 16
documents.
A total of 375 documents listed ocular/ophthalmic
problems as complications of SJS/TEN, 26 mentioned
urinary tract infections, and 95 mentioned sepsis/
septicemia.
Genetic predisposition
A total of 65 documents discussed the genetic risk fac-
tors for developing SJS and TEN. Visualization map for
terms present in title/abstract of these documents is
shown in Fig. 11. The map consisted of three cluster
(red, green and blue). Each cluster represents terms that
were commonly mentioned together. Cluster number
one included the following items: (carbamazepine/CBZ,
genetic marker, Han Chinese/Han Chinese population,
HLA b allele, HLA b 1502/HLA b 1502 allele, phenytoin,
Table 4 List of active countries/territoris in publishing on SJS and TEN
Country/Territory Frequency % N = 3856 Number of collaborating countries SCP Percent MCP Percent
United States 640 16.60 36 572 89.38 68 10.63
Japan 237 6.15 7 225 94.94 12 5.06
France 234 6.07 19 193 82.48 41 17.52
United Kingdom 199 5.16 16 178 89.45 21 10.55
Germany 163 4.23 19 121 74.23 42 25.77
India 159 4.12 6 153 96.23 6 3.77
Italy 152 3.94 14 133 87.50 19 12.50
Spain 136 3.53 1 134 98.53 2 1.47
Turkey 71 1.84 3 68 95.77 3 4.23
South Korea 70 1.82 4 66 94.29 4 5.71
Taiwan 68 1.76 8 59 86.76 9 13.24
Canada 58 1.50 10 43 74.14 15 25.86
Belgium 54 1.40 4 49 90.74 5 9.26
Poland 50 1.30 4 49 98.00 1 2.00
Australia 46 1.19 4 43 93.48 3 6.52
China 45 1.17 4 37 82.22 8 17.78
Netherlands 44 1.14 8 33 75.00 11 25.00
Switzerland 40 1.04 9 27 67.50 13 32.50
Singapore 37 0.96 9 30 81.08 7 18.92
Israel 36 0.93 9 25 69.44 11 30.56
Brazil 28 0.73 7 22 78.57 6 21.43
Portugal 26 0.67 5 22 84.62 4 15.38
Austria 25 0.65 8 17 68.00 8 32.00
Mexico 22 0.57 4 18 81.82 4 18.18
SJS Stevens – Johnson Syndrome
TEN Toxic Epidermal Necrolysis
SCP Single Country Publication (intra-country publication)
MCP Multiple Country Publication (inter-country publication = International collaboration)
Sweileh Orphanet Journal of Rare Diseases  (2017) 12:14 Page 7 of 15
and Taiwan. The second cluster included the following
items: (gene, genetic predisposition, HLA-A, HLA-A0206,
HLA class, Human Leukocyte Antigen, Japanese patients,
and Ocular complications. The third cluster included the
following terms: (Allopurinol, HLA allele, HLA-B 5801,
and Japanese).
Discussion
In this study, we presented a bibliometric overview of lit-
erature on SJS and TEN published in the past seven de-
cades. SJS and TEN are associated with high mortality
rate and medications play a role as causative agents of
SJS and TEN. Therefore, SJS and TEN are conditions
Fig. 5 a Productivity of various world regions. b Geographic distribution of SJS and TEN publications using ArcMap 10.1 software
Fig. 6 Network visualization map of citations for articles produced by active countries
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with multidisciplinary aspects from a research and clin-
ical management points of view [49, 50]. Our results
showed that international collaboration in research per-
taining to SJS and TEN is relatively low when compared
with other fields. This might be due to the clinical na-
ture and time course of the conditions. SJS and TEN are
not chronic condition and except for the genetic
component of these conditions, little can be done for
international collaboration in research on SJS and TEN.
Our study showed that number of publications on SJS
and TEN increased slowly and gradually over the past
half century. This increase might be due to natural
growth of medical publications in the past half century
or due to increased reported cases of drug-induced SJS
Fig. 7 Network visualization map of country co-authorship (international collaboration)
Fig. 8 Active institutions in publishing about SJS and TEN
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and TEN in the past half century. No doubt that the in-
creasing number of newly approved drugs could be asso-
ciated with new cases of SJS and TEN. Another potential
explanation for the increased number of publications on
SJS and TEN is the potential association of some infec-
tious diseases such as Mycoplasma pneumonia, HIV,
hepatitis, Cytomegalovirus, and others with SJS and
TEN.
Our study showed that only two thirds of retrieved ar-
ticles were in English. This suggests that cases of SJS
and TEN are found and reported by non-English language
from all over the world. Results of our study indicated that
countries in northern America, Latin America, Europe,
Middle East, and Southeast Asia were among active coun-
tries in publishing on SJS and TEN. Together with the
high value of h-index of retrieved documents, it can be
deduced that SJS and TEN are considered a serious and
important research topic with high number of readers.
Furthermore, the fact that some journals in the active list
have high IF is suggestive of the clinical importance of SJS
and TEN as a research and medical topic.
Our finding that the USA had the largest share of
publications was not surprising given the huge budget
allocated for research and the vast number of research
centers in the USA. Several bibliometric studies on
various medical topics concluded that the USA ranked
first in research productivity [39, 40, 51–53]. However,
it was surprising that most active authors were either
French or Japanese and none were Americans. This
could be attributed to regional differences in commonly
prescribed drugs or due to differences in genetic predis-
position [54, 55]. The analysis of Japanese Adverse
Table 5 Active authors in publishing articles on SJS and TEN
Author Frequency % N = 3856 h-index Country Affiliation
Roujeau, J.C. 113 2.93 48 France
Revuz, J. 57 1.48 28 France
Mockenhaupt, M. 51 1.32 23 Germany
Sotozono, C. 39 1.01 18 Japan
Paquet, P. 36 0.93 17 Belgium
Ueta, M. 30 0.78 13 Japan
Wolkenstein, P. 29 0.75 17 France
Aihara, M. 25 0.65 10 Japan
Touraine, R. 22 0.57 10 France
Piérard, G.E. 26 0.67 16 Belgium
Valeyrie-Allanore, L. 20 0.52 9 France
h-index Hirsch index
SJS Stevens – Johnson Syndrome
TEN Toxic Epidermal Necrolysis
Fig. 9 Co-citation analysis of active authors publishing articles on SJS and TEN
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Table 6 Active journals in publishing articles on SJS and TEN
Journal Frequency % N = 3856 IF
Archives of Dermatology 123 3.19 0.14
British Journal of Dermatology 88 2.28 4.275
Lancet 83 2.15 45.217
Journal of The American Academy of Dermatology 80 2.07 4.449
International Journal of Dermatology 63 1.63 1.312
Clinical and Experimental Dermatology 46 1.19 1.315
Acta Dermato Venereologica 39 1.01 0.54
Journal of Dermatology 39 1.01 1.577
Annales De Dermatologie Et De Venereologie 36 0.93 0.07
Klinicheskaya Meditsina 33 0.86 0.08
Dermatology 32 0.83 1.569
Journal of Burn Care and Research 32 0.83 1.37
American Journal of Ophthalmology 30 0.78 3.831
British Medical Journal 28 0.73 19.967
Burns 28 0.73 0.89
Journal of The European Academy of Dermatology and Venereology 28 0.73 2.826
Korean Journal of Dermatology 27 0.70 0.04
Pediatric Dermatology 27 0.70 1.163
Actas Dermo Sifiliograficas 26 0.67 0.61
Annals of Pharmacotherapy 26 0.67 2.35
Journal of Burn Care and Rehabilitation 26 0.67 N/A
Indian Journal of Dermatology Venereology and Leprology 25 0.65 1.488
Cornea 21 0.54 1.18
Bulletin De La Societe Francaise De Dermatologie Et De Syphiligraphie 20 0.52 N/A
IF impact factor
N/A not applicable
SJS Stevens – Johnson Syndrome
TEN Toxic Epidermal Necrolysis
Fig. 10 Citation analysis of active journals in publishing articles on SJS and TEN
Sweileh Orphanet Journal of Rare Diseases  (2017) 12:14 Page 11 of 15
Drug Event Report (JADER) database and analysis of
the time-to-onset profile of SJS and TEN yielded data
that are different from the Europeans [54]. A similar
study was the EuroSCAR-study which is a multicenter
European study carried out to evaluate medication in-
duced severe cutaneous adverse reactions (SCAR) [55].
The EuroSCAR registry classified drugs that induce
SJS/TEN into high, moderate, and low risk drugs with
allopurinol and carbamazepine being in the high-risk
category [56].
Our study showed that anti-epileptic drugs, particularly
carbamazepine, phenytoin, lamotrigene and others were
most commonly encountered in SJS and TEN literature.
Different studies reported different main causative drugs
of SJS and TEN possibly due to ethnic and genetic varia-
tions or due to different types of prescribing pattern. An
Indian multicentric retrospective study of drug – induced
SJS and TEN found that antimicrobials, nonsteroidal anti-
inflammatory drugs, and antiseizure drugs were the most
commonly associated groups with SJS and TEN and that
antiseizure drugs were more often associated with TEN
than other drugs [57]. A 20-year study in children in ter-
tiary care hospital in Thailand found that antiepileptic
drug group was the most common causative drug,
followed by antibiotic drug group, and others which in-
cluded nonsteroidal antiinflammtory drugs (NSAIDs) and
chemotherapy drugs [10]. A study in Indonesia found
that most common causative drugs were paracetamol,
carbamazepine, amoxicillin, ibuprofen, rifampicin, and
trihexyphenidyl [58].
Our study showed and emphasized previous findings
of associations between certain genes and drug – induced
SJS/TEN. For example, SJS/TEN induced by anti-
epileptics such as carbamazepine and phenytoin is asso-
ciated with HLA-B*15:02 in Han Chinese people [59].
Association of HLA-A 31:01 with carbamazepine –
induced SJS have been reported in children [60]. A
study in Thailand concluded that there is an association
between HLAB (*) 58:01 and allopurinol-induced SJS-
TEN in a Thai population [61]. Similar findings were
obtained in Korean cases [62]. Presence of sever ocular
complications in SJS/TEN have been linked to certain
HLA types such as HLA-A*02:06 [63].
The top cited articles on SJS and TEN discussed sev-
eral important issues in the field including ones on
medication – induced SJS and TEN, genetic and ethnic
role, illness severity scoring, treatment potential and
others. The role of immunoglobulin in treatment of SJS/
TEN is one of the top cited issues on SJS and TEN.
Intravenous immunoglobulin as a therapeutic option has
shown efficacy in reducing length of skin reactions and
reducing severity of symptoms [64–66]. Recent pub-
lished guidelines for the management of SJS and TEN
included the removal of offending cause plus the initi-
ation of high dose parenteral corticosteroids [67]. Use of
plasmapheresis as an adjuvant therapy in SJS and TEN
have shown beneficial effects [68–71].
Bibliometric studies are not without limitations. Des-
pite that Scopus is the largest database available, articles
published in non-indexed journals were not included in
this study. Furthermore, the interchangeable use of SJS
and EMM in the 1980s made the accuracy of results ob-
tained during that period less than ideal. The keywords
were used in title search which might have caused some
data loss. However, title search is important to maintain
high level accuracy and minimize false positive results.
Scopus database retrieved not only countries but also
distinct territories and that is why China and Taiwan ap-
peared as separate countries/territories in genetic map
despite that both are of similar ethnic group because
Scopus database has China and Taiwan as separate en-
tities/territories. Finally, the use of Web of Science
(WoS) is believed to give data published in journals with
impact factor as reported by Journal Citation Report.
Fig. 11 Network visualization map of predisposing genetic factors to SJS and TEN
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Therefore, WoS is believed to retrieve data in influential
journals. In this manuscript we sought to cover the lar-
gest number of publications and therefore we did not
utilize WoS.
Conclusion
Our study showed that there was a gradual growth of
publications on SJS and TEN in the past six decades.
Bibliometric analysis of literature on SJS and The USA is
important for clinicians and research to pinpoint gaps
and understand worldwide aspect of these conditions re-
garding differential epidemiology and ethnic variations.
Young researchers will learn from such bibliometric ana-
lysis studies about top cited articles on the conditions
and names of institutions and authors who are leaders in
the subject. Mapping genetic background and ethnicities
is also of benefit for understanding medication – induced
SJS and TEN among various ethnic groups. Despite the
importance of the topic, the extent of international collab-
oration on the topic was relatively low, something which
needs to addressed and encouraged.
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